Present

Mallax Pharmaceuticals

Mallax Pharmaceuticals was established in Q4 2020 by Impilo together with Anders Larnholt, an experienced pharma executive, as a pharma company ‘ready-to-use’ with required pharmaceutical processes and licenses.

Impilo’s ambition is to invest significant capital and resources in building a platform of established pharmaceuticals and OTC products for customers and patients across Europe - with a wide size range for any individual deal between EUR 10m and EUR 300m.

Responsible partner:Magnus Edlund

Board member:Magnus Edlund

Industry:Pharmaceuticals / OTC

CEO:Anders Larnholt

Acquisition date:December 2020

Homepage: http://www.mallaxpharma.com/